Early metabolic markers of the development of dysglycemia and type 2 diabetes and their physiological significance

Diabetes

Volumn 62, Issue 5, 2013, Pages 1730-1737

  Ferrannini, Ele ^a   Natali, Andrea ^a   Camastra, Stefania ^a   Nannipieri, Monica ^a   Mari, Andrea ^b   Adam, Klaus Peter ^c   Milburn, Michael V ^c   Kastenmüller, Gabi ^d   Adamski, Jerzy ^d   Tuomi, Tiinamaija ^e,f   Lyssenko, Valeriya ^g   Groop, Leif ^g   Gall, Walter E ^c  

^a UNIVERSITY OF PISA   (Italy)

^b CNR   (Italy)

^c METABOLON INC   (United States)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^f FOLKHÄLSAN RESEARCH CENTER   (Finland)

^g LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYBUTYRIC ACID; BIOLOGICAL MARKER; FATTY ACID; GLUCOSE; HYDROXYBUTYRIC ACID; INSULIN; LINOLEOYL GLYCEROPHOSPHOCHOLINE; PHOSPHORYLCHOLINE; UNCLASSIFIED DRUG;

ACCURACY; ADULT; AGED; ARTICLE; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; DIET RESTRICTION; DYSGLYCEMIA; FAMILIAL DISEASE; FATTY ACID BLOOD LEVEL; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GROUPS BY AGE; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SEX DIFFERENCE;

ADULT; ANIMALS; BIOLOGICAL MARKERS; CELL LINE; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; EARLY DIAGNOSIS; FEMALE; FOLLOW-UP STUDIES; GLUCOSE METABOLISM DISORDERS; HUMANS; HYDROXYBUTYRATES; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; PHOSPHATIDYLCHOLINES; PROSPECTIVE STUDIES; RATS; ROC CURVE;

EID: 84876575039     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db12-0707     Document Type: Article

References (41)

1. Newgard CB, An J, Bain JR, et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metab 2009;9:311-326
2. Huffman KM, Shah SH, Stevens RD, et al. Relationships between circulating metabolic intermediates and insulin action in overweight to obese, inactive men and women. Diabetes Care 2009;32:1678-1683
3. Shah SH, Svetkey LP, Newgard CB. Branching out for detection of type 2 diabetes. Cell Metab 2011;13:491-492
4. Kolak M, Westerbacka J, Velagapudi VR, et al. Adipose tissue inflammation and increased ceramide content characterize subjects with high liver fat content independent of obesity. Diabetes 2007;56:1960-1968 (Pubitemid 47195815)
5. Wang TJ, Larson MG, Vasan RS, et al. Metabolite profiles and the risk of developing diabetes. Nat Med 2011;17:448-453
6. Gall WE, Beebe K, Lawton KA, et al.; RISC Study Group. alpha-hydroxybutyrate is an early biomarker of insulin resistance and glucose intolerance in a nondiabetic population. PLoS ONE 2010;5:e10883
7. Lyssenko V, Jonsson A, Almgren P, et al. Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med 2008;359:2220-2232
8. Hills SA, Balkau B, Coppack SW, et al.; EGIR-RISC Study Group. The EGIR-RISC STUDY (The European group for the study of insulin resistance: relationship between insulin sensitivity and cardiovascular disease risk): I. Methodology and objectives. Diabetologia 2004;47:566-570 (Pubitemid 38491256)
9. Ferrannini E, Balkau B, Coppack SW, et al.; RISC Investigators. Insulin resistance, insulin response, and obesity as indicators of metabolic risk. J Clin Endocrinol Metab 2007;92:2885-2892
10. Ferrannini E, Natali A, Muscelli E, et al.; RISC Investigators. Natural history and physiological determinants of changes in glucose tolerance in a non-diabetic population: the RISC Study. Diabetologia 2011;54:1507-1516
11. Groop L, Forsblom C, Lehtovirta M, et al. Metabolic consequences of a family history of NIDDM (the Botnia study): evidence for sex-specific parental effects. Diabetes 1996;45:1585-1593 (Pubitemid 26357553)
12. Stumvoll M, Mitrakou A, Pimenta W, et al. Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care 2000;23:295-301 (Pubitemid 30131733)
13. Mari A, Schmitz O, Gastaldelli A, Oestergaard T, Nyholm B, Ferrannini E. Meal and oral glucose tests for assessment of beta-cell function: modeling analysis in normal subjects. Am J Physiol Endocrinol Metab 2002;283:E1159-E1166 (Pubitemid 35340621)
14. Van Cauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 1992;41:368-377
15. Ferrannini E. Insulin resistance versus insulin de ficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Endocr Rev 1998;19:477-490 (Pubitemid 29116377)
16. Laakso M. How good a marker is insulin level for insulin resistance? Am J Epidemiol 1993;137:959-965 (Pubitemid 23191063)
17. Hanson RL, Pratley RE, Bogardus C, et al. Evaluation of simple indices of insulin sensitivity and insulin secretion for use in epidemiologic studies. Am J Epidemiol 2000;151:190-198 (Pubitemid 30463650)
18. Hanley AJ, Williams K, Gonzalez C, et al.; San Antonio Heart Study; Mexico City Diabetes Study; Insulin Resistance Atherosclerosis Study. Prediction of type 2 diabetes using simple measures of insulin resistance: combined results from the San Antonio Heart Study, the Mexico City Diabetes Study, and the Insulin Resistance Atherosclerosis Study. Diabetes 2003;52:463-469 (Pubitemid 36173204)
19. Mari A, Ferrannini E. Beta-cell function assessment from modelling of oral tests: an effective approach. Diabetes Obes Metab 2008;10(Suppl. 4):77-87
20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419 (Pubitemid 15018832)
21. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462-1470 (Pubitemid 29418240)
22. Porte D Jr. Normal physiology and phenotypic characterization of beta-cell function in subjects at risk for non-insulin-dependent diabetes mellitus. Diabet Med 1996;13(Suppl. 6):S25-S32
23. Ferrannini E, Mari A. Beta cell function and its relation to insulin action in humans: a critical appraisal. Diabetologia 2004;47:943-956 (Pubitemid 38757009)
24. Reaven GM. Insulin secretory function in type 2 diabetes: does it matter how you measure it? J Diabetes 2009;1:142 -150
25. Soga T, Ohishi T, Matsui T, et al. Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor. Biochem Biophys Res Commun 2005;326:744-751 (Pubitemid 39655983)
26. Chu ZL, Jones RM, He H, et al. A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. Endocrinology 2007;148:2601-2609 (Pubitemid 46984798)
27. Lan H, Lin HV, Wang CF, et al. Agonists at GPR119 mediate secretion of GLP-1 from mouse enteroendocrine cells through glucose-independent pathways. Br J Pharmacol 2012;165:2799-2807
28. Yea K, Kim J, Yoon JH, et al. Lysophosphatidylcholine activates adipocyte glucose uptake and lowers blood glucose levels in murine models of diabetes. J Biol Chem 2009;284:33833-33840
29. Yea K, Kim J, Lim S, et al. Lysophosphatidylserine regulates blood glucose by enhancing glucose transport in myotubes and adipocytes. Biochem Biophys Res Commun 2009;378:783-788
30. Adams SH. Emerging perspectives on essential amino acid metabolism in obesity and the insulin-resistant state. Adv Nutr 2011;2:445-456
31. Fiehn O, Garvey WT, Newman JW, Lok KH, Hoppel CL, Adams SH. Plasma metabolomic profiles reflective of glucose homeostasis in non-diabetic and type 2 diabetic obese African-American women. PLoS ONE 2010;5:e15234
32. Perseghin G, Ghosh S, Gerow K, Shulman GI. Metabolic defects in lean nondiabetic offspring of NIDDM parents: a cross-sectional study. Diabetes 1997;46:1001-1009 (Pubitemid 27221001)
33. Groop LC, Ferrannini E. Insulin action and substrate competition. Baillieres Clin Endocrinol Metab 1993;7:1007-1032 (Pubitemid 23332522)
34. Karpe F, Dickmann JR, Frayn KN. Fatty acids, obesity, and insulin resistance: time for a reevaluation. Diabetes 2011;60:2441-2449
35. Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med 2012;52:59-69
36. Bonadonna RC, Saccomani MP, Cobelli C, DeFronzo RA. Effect of insulin on system A amino acid transport in human skeletal muscle. J Clin Invest 1993;91:514-521 (Pubitemid 23064136)
37. Pereira S, Marliss EB, Morais JA, Chevalier S, Gougeon R. Insulin resistance of protein metabolism in type 2 diabetes. Diabetes 2008;57:56-63
38. Felig P, Marliss E, Cahill GF Jr. Plasma amino acid levels and insulin secretion in obesity. N Engl J Med 1969;281:811-816
39. Tessari P, Cecchet D, Cosma A, et al. Insulin resistance of amino acid and protein metabolism in type 2 diabetes. Clin Nutr 2011;30:267-272
40. Adeva MM, Calviño J, Souto G, Donapetry C. Insulin resistance and the metabolism of branched-chain amino acids in humans. Amino Acids 2012;43:171-181
41. Cheng Z, Tseng Y, White MF. Insulin signaling meets mitochondria in metabolism. Trends Endocrinol Metab 2010;21:589-598